ストックスクリーナーアプリを入手
19.03
1.98%
0.37
アフターアワーズ：
19.03
前日終値:
$18.66
開ける：
$18.98
24時間の取引高:
146.56K
Relative Volume:
0.54
時価総額：
$914.04M
収益：
-
当期純損益:
-
株価収益率:
-6.1488
EPS:
-3.0949
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+8.25%
1か月 パフォーマンス:
+5.37%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$18.30
$19.61
1週間の範囲:
$17.20
$19.61
52週間の値動き範囲:
$15.10
$20.00
Odyssey Therapeutics Inc Stock (ODTX) Company Profile
Compare ODTX vs VRTX, REGN, ARGX, RVMD, ALNY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ODTX
Odyssey Therapeutics Inc
|
19.03 | 896.26M | 0 | 0 | 0 | -3.0949 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Odyssey Therapeutics Inc (ODTX) 最新ニュース
Odyssey Therapeutics, Inc. Revenue Breakdown – NASDAQ:ODTX - TradingView
Odyssey Therapeutics Ord Shs (Proposed) (ODTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ODTX|Odyssey Therapeutics Ord Shs (Proposed)|Price:18.660|Chg%:+0.990 - TradingKey
Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower - Stocktwits
ODTX Price Today: Odyssey Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - mexc.co
Odyssey Therapeutics (ODTX) Earnings Date and Reports 2026 - MarketBeat
Enterprise value to revenue forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Price to book forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Price to earnings forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Price to sales forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Odyssey Therapeutics prices upsized IPO at $18 per share - Investing.com
Odyssey Therapeutics Inc (ODTX) Dividend News Alerts - DividendInvestor.com
Enterprise value to EBIT forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Odyssey Therapeutics (ODTX) Stock Trends and Sentiment 2026 - MarketBeat
Form 8K ODYSSEY THERAPEUTICS For: 23 June By Investing.com - Investing.com Nigeria
Odyssey posts June 2026 corporate presentation highlighting OD-001 Phase 2a results and $464M pro forma cash - TradingView
Odyssey Therapeutics (NASDAQ: ODTX) details I&I pipeline, OD-001 data and cash - Stock Titan
ODTX Stock Price and Chart — NASDAQ:ODTX - TradingView
Odyssey Therapeutics, Inc.(NasdaqCM: ODTX) added to S&P TMI Index - marketscreener.com
Odyssey Therapeutics, Inc. (ODTX) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Analysts Offer Insights on Healthcare Companies: Odyssey Therapeutics, Inc. (ODTX), Capricor Therapeutics (CAPR) and Medtronic (MDT) - The Globe and Mail
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO - BioSpace
TD Cowen Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating - Moomoo
ODTX Reiterated by Oppenheimer -- Price Target Maintained at $40 - GuruFocus
Oppenheimer Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Odyssey Therapeutics: Q1 Earnings Snapshot - AOL.com
Odyssey Therapeutics, Inc. 2026 Q1 10-Q Report: Clinical Progress, Risk Factors, and Financial Overview - Minichart
Odyssey Therapeutics Q1 EPS $(6.77) misses $(1.13) estimate - scanx.trade
Odyssey Therapeutics reports Q1 2026: $38.3M net loss, $464.4M pro forma cash to fund into H2 2028 - TradingView
Odyssey Therapeutics, Inc. 1Q 2026: Revenue $0 EPS $(6.77) — 10-Q Summary - TradingView
ODTX: Strong clinical progress and IPO proceeds position the company for late-stage development - TradingView
ODTX SEC FilingsODYSSEY THERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Odyssey Therapeutics (Nasdaq: ODTX) posts Q1 loss but secures $464M cash - Stock Titan
Odyssey Therapeutics reports positive OD-001 data and $464.4M cash position - scanx.trade
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Odyssey Therapeutics Reports Positive Phase 2a Proof-of-Concept Data for OD-001 in Ulcerative Colitis and Q1 2026 Financial Results - Quiver Quantitative
Odyssey Therapeutics sees ulcerative colitis signal in Phase 2a trial - Stock Titan
Wedbush Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
FMR LLC's Strategic Acquisition of Odyssey Therapeutics Inc Shar - GuruFocus
Anthony W. Opipari Net Worth (2026) - GuruFocus
Odyssey Therapeutics Inc (ODTX) 財務データ
収益
当期純利益
現金流量
EPS
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):